Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show more

Location: Mailpoint 810, South Block, Southampton, SO16 6YD, United Kingdom | Website: https://www.synairgen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.097M

52 Wk Range

$0.00 - $0.07

Previous Close

$0.00

Open

$0.00

Volume

400

Day Range

$0.00 - $0.00

Enterprise Value

-8.531M

Cash

8.591M

Avg Qtr Burn

-11.96M

Insider Ownership

0.57%

Institutional Own.

87.22%

Qtr Updated

06/30/24